| Aug 7 |
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
|
| Aug 7 |
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
|
| Aug 6 |
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
| Aug 6 |
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
|
| Aug 6 |
Exelixis: Q2 Earnings Snapshot
|
| Aug 6 |
Exelixis beats top-line and bottom-line estimates; raises FY24 revenue outlook
|
| Aug 6 |
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 6 |
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
|
| Aug 6 |
FDA accepts Exelixis sNDA for Cabometyx for neuroendocrine tumors
|
